WITH YOUR PARTICIPATION,
WE’RE LEARNING MORE
ABOUT THE FIGHT AGAINST
ALZHEIMER’S DISEASE

If you or a loved one have been diagnosed with mild-to-moderate Alzheimer’s disease, you may be able to participate in a clinical research study to evaluate the safety and tolerability of a new investigational medicine and its role in slowing cognitive and functional decline.

SEE IF YOU PRE-QUALIFY FOR ONE OF THESE STUDIES
STUDY-RELATED CARE WILL BE PROVIDED AT NO COST TO YOU.

Participation in the rethinkALZ and refocusALZ clinical research studies may help slow disease progression and improve thinking and memory in patients with Alzheimer’s disease.

To meet study eligibility criteria, the participant must:

  • Be 50-87 years-of-age
  • Report a gradual and progressive change in memory for more than six months
  • Have a diagnosis of Alzheimer’s disease consistent with Stage 4 or Stage 5 on the Alzheimer’s continuum

OUR SCIENCE IS BASED ON STABILIZING A CRITICAL PROTEIN IN THE BRAIN.

Simufilam is the investigational drug that is being tested in the rethinkALZ and refocusALZ clinical trials. View the video to learn more.

[ CLIENT PROVIDED INFORMATION ON THE ACRONYMS ] diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nos trud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendre rit in vulputate velit esse molestie consequat, vel illum